Telix launches U.S. commercial dosing of FDA‑approved brain cancer imaging drug Pixclara
Telix Pharmaceuticals announced that the first U.S. patients were dosed with Pixclara, its FDA‑approved PET imaging agent for glioma, on Oct. 6 2026 in Indianapolis and Cleveland. The drug is supplied by PharmaLogic Holdings and is the only radiopharmaceutical approved for this indication. Pixclara helps clinicians differentiate recurrent or progressive glioma from treatment‑related changes in adults and children one month old and older. The company highlighted the unmet need, noting roughly 24,000 new glioma cases are diagnosed each year in the United States.
Why it matters
The launch makes the only FDA‑approved glioma imaging agent commercially available in the U.S., potentially expanding Telix’s revenue base beyond its existing prostate imaging portfolio. The company’s stock rose 3.13% to $10.88 after the announcement, indicating market optimism about the new product’s sales prospects.
Key facts
- 1First doses were administered at Indiana University Health Neuroscience Center in Indianapolis and University Hospitals Cleveland Medical Center on Oct. 6 2026. globenewswire.com
- 2Pixclara is the only FDA‑approved radiopharmaceutical imaging drug for glioma. globenewswire.com
- 3Pixclara is indicated for adults and pediatric patients one month of age and older. globenewswire.com
- 4PharmaLogic Holdings Corp. supplies finished unit doses to the U.S. market. globenewswire.com
- 5Telix previously forecast 2026 revenue of US$950 million to US$970 million but gave no specific Pixclara sales target. mugglehead.com
- 6The stock closed at $10.88, up 3.13%, and was trading at $10.98 in pre‑market after the news. rttnews.com
Summary written by AlphAI from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.